WASHINGTON — The U.S. government has canceled a multibillion-dollar deal with the Washington, D.C., firm that makes a type of vaccine for Ebola and other deadly viruses because of the company’s failure to obtain proper FDA approval, according to a federal notice.
A joint statement from the Department of Health and Human Services and the Food and Drug Administration announced Tuesday the cancellation of the anticipated contract with Baxter International, which was to make a “challenge vaccine” for Ebola.
The contract was expected to pay a third of the cost of the Ebola vaccine, under which the Maryland company was to have produced several million doses of the vaccine for trial in human trials. The effort would have tested the vaccine in African health care workers, though scientists have said human testing could begin by the end of the year.
A Baxter spokesperson said the cancellation of the contract stemmed from a lack of adequate information. The company said it learned the deal was being canceled from a news report earlier this month.